Quick Answer
MiNK Therapeutics, Inc. reported Research And Development Expense of $5.76 million for the year ending 2025.
- MiNK Therapeutics, Inc. showed a decrease of -9.1% in Research And Development Expense from 2024 to 2025.
- This data is from MiNK Therapeutics, Inc.'s annual report (Form 10-K), filed with the SEC on March 31, 2026.
- XBRL data for this metric is available from 2020 to 2025 (6 years of filings). Earlier data may not exist in machine-readable XBRL format as companies adopted electronic filing at different times.
- Over the full 6 years of available data (2020 to 2025), MiNK Therapeutics, Inc.'s Research And Development Expense has declined by 39.5%.
- Historical annual values: Fiscal year 2025: $5.76 million | Fiscal year 2024: $6.34 million | Fiscal year 2023: $15.49 million | Fiscal year 2022: $23.12 million | Fiscal year 2021: $13.97 million | Fiscal year 2020: $9.51 million.
- Data sourced from SEC EDGAR public filings as of June 20, 2026.
Last verified: